CheckMyRecalls

Merck & Co. Inc recalls Belsomra (suvorexant) tablets

Published
20 Aug 2025
Units affected
51,320 cartons
Agency
FDA
Country
United States

The hazard

Failed Dissolution Specifications: potential for delayed dissolution of the dose after administration which may result in delayed release of the drug, delaying onset of sleep.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Belsomra (suvorexant) tablets, 10mg, 30 Tablets in 3 Blister Cards per Carton, Each Blister Card contains 10 Tablets, Rx only, Merck Sharp & Dohme LLC, Rahway, NJ 07065, USA, NDC 0006-0033-10 (Shellpack and Print Mat Labels), 0006-0033-30 (Carton Label)

Brand / company
Merck & Co. Inc
Codes / lots
Lots 2090019 and 2123744, Exp. 4/30/2027
Distribution
Nationwide in the USA and PR.
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 20 Aug 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.